<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220108053663N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-09</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of Spirulina platensis algae in the treatment of diabetes</public_title>
      <acronym></acronym>
      <scientific_title>Survey and Comparison of the effect of fortified yogurt enriched with fermented and non-fermented Spirulina Platensis extract on reducing oxidative stress in patients with type 2 diabetes mellitus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65709</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: In this study, spirulina algae is fermented and the effect of fermented type of algae is compared with non-fermented algae, Randomization description: This study is a double-blind randomized clinical trial study, which was considered by the diabetes clinic affiliated to Arak University of Medical Sciences to select patients with type 2 diabetes in the age group of 40-70 years. After voluntarily choosing 100 patients to participate in the study and providing explanations about the goals of the project and after obtaining their informed consent to participate in the study, a list of participants is prepared and coded. And the codes are entered in SPSS statistical software and using simple randomization method, people are divided into two groups of 50 people, Blinding description: The intervention is a type of double-blind randomized clinical trial. None of the participants and examiners will know about the allocation of groups to the intervention under study. The intended intervention is similar in terms of appearance (smell, color, appearance, etc.).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 diabetes mellitus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After the patients visited the diabetes clinic for the plan, full explanations about the objectives of the study will be given to them during a one-hour training session. Then, after obtaining their informed written permission and consent to voluntarily participate in the study, people are randomly divided into two groups of 50 people, 50 type  2 diabetic patients, daily 200 grams of low-fat yogurt containing 20 grams of non-fermented spirulina algae powder. It is suggested that the patient consumes 100 grams of yogurt in two meals for 21 days. Algae powder manufacturer is Berkeh Sabz Mad Asia Company, and it is one of the factories in the country and has a health license from the Vice-Chancellor of Food and Medicine of Arak University of Medical Sciences. Intervention 2: Intervention group: After the patients visited the diabetes clinic for the plan, full explanations about the objectives of the study will be given to them during a one-hour training session. Then, after obtaining their informed written permission and consent to voluntarily participate in the  study, people are randomly divided into two groups of 50 people, 50 type 2 diabetic patients, daily 200 grams of low-fat yogurt containing 20 grams of fermented spirulina algae powder. It is suggested that the patient consumes 100 grams of yogurt in two meals for 21 days. Algae powder manufacturer is Berkeh Sabz Mad Asia Company, and it is one of the factories in the country and has a health license from the Vice-Chancellor of Food and Medicine of Arak University of Medical Sciences.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The individual information of the participants without the names of the people, the spss file includes the results of fasting blood sugar, malondialdehyde, glutathione regeneration and the total antioxidant level of the blood serum of the patients can be shared. Statistical tests cannot be delegated.

When:
starting in september 2023

To whom:
Researchers working in academic and scientific institutions

Conditions:
No special conditions are required.

Where to obtain:
Refer to the email below.
aida_gh60@yahoo.com

How to obtain:
Two weeks after submitting the application

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Anoosheh Sharifan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Science and Research branch, Islamic Azad University</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1477893855</zip>
        <telephone>+98 21 4486 5154</telephone>
        <email>a_sharifan2000@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ayda Ghaffari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>no108- Sefid Tower, Mirza Shirazi street</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3815937458</zip>
        <telephone>+98 86 3276 0036</telephone>
        <email>AIDA_GH60@YAHOO.COM</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Type 2 diabetes mellitus</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Type1 diabetes mellitus
Patients injecting insulin
Age less than 40 and more than 70 years</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After the patients visited the diabetes clinic for the plan, full explanations about the objectives of the study will be given to them during a one-hour training session. Then, after obtaining their informed written permission and consent to voluntarily participate in the study, people are randomly divided into two groups of 50 people, 50 type  2 diabetic patients, daily 200 grams of low-fat yogurt containing 20 grams of non-fermented spirulina algae powder. It is suggested that the patient consumes 100 grams of yogurt in two meals for 21 days. Algae powder manufacturer is Berkeh Sabz Mad Asia Company, and it is one of the factories in the country and has a health license from the Vice-Chancellor of Food and Medicine of Arak University of Medical Sciences.</i_keyword>
      <i_keyword>Intervention group: After the patients visited the diabetes clinic for the plan, full explanations about the objectives of the study will be given to them during a one-hour training session. Then, after obtaining their informed written permission and consent to voluntarily participate in the  study, people are randomly divided into two groups of 50 people, 50 type 2 diabetic patients, daily 200 grams of low-fat yogurt containing 20 grams of fermented spirulina algae powder. It is suggested that the patient consumes 100 grams of yogurt in two meals for 21 days. Algae powder manufacturer is Berkeh Sabz Mad Asia Company, and it is one of the factories in the country and has a health license from the Vice-Chancellor of Food and Medicine of Arak University of Medical Sciences.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Average changes in  reduced glutathione levels in the blood serum of type 2 diabetics. Timepoint: Measurement of blood  reduced glutathione levels before the intervention and 21 days after the intervention. Method of measurement: reduced glutathione blood level measurement kit.</prim_outcome>
      <prim_outcome>Average changes in fasting blood sugar levels in the blood serum of type 2 diabetics. Timepoint: Measurement of fasting blood sugar before the intervention and 21 days after the intervention. Method of measurement: fasting blood sugar measurement kit.</prim_outcome>
      <prim_outcome>Average changes in high reactive protein C level in blood serum of type 2 diabetic patients. Timepoint: Measurement of C protein with high reactivity in blood serum before the intervention and 21 days after the intervention. Method of measurement: C- Reactive protein measurement kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Malondialdehyde( MDA). Timepoint: Malondialdehyde content is measured before and 21 days after consumption of yogurt enriched with fermented and non-fermented Spirulina Platensis. Method of measurement: diagnostic malondialdehyde assay kit.</sec_outcome>
      <sec_outcome>Ferric Reducing Ability of Plasma( FRAP). Timepoint: Before starting consumption and 21 days after starting consumption of yogurt enriched with fermented and non-fermented spirulina platensis, the antioxidant capacity of total plasma is measured. Method of measurement: FRAP Detection Assay Kit.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak Medical University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-22</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University Science and Research Unit</contact_name>
        <contact_address>Islamic Azad University, Department of Science and Research - Sattari Blvd Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
